Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 10;15:57. doi: 10.1186/s13048-022-00984-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 4 — ZBP1 knockdown increased the migration of A2780 cells, blocking fisetin-induced apoptosis. (A) Western blotting of both the ZBP1 knockdown (ZBP1^−/−) group and the control group, in which A2780 cells were treated with fisetin + z-VAD. (B) Quantification of ZBP1 expression with or without ZBP siRNA administration. (C) In vitro invasion assay between the respective groups. (D) MTT assay indicated differences in cell migration between the indicated groups. (E) Western blotting and (F) quantitative expression levels targeting RIP3 and MLKL in both ZBP1^−/− and normal A2780 cells, both of which were treated with fisetin + z-VAD. *, p < 0.05